explore -WSS

explore

author：focus 2025-09-06 05:26:45 - browse：31756

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： A disappointing year of Humira biosimilars

knowledge

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Steward Health Care Massachusetts hospitals face fiscal disaster

Key House Republican on health care plans exit from Congress

RaDonda Vaught links Vanderbilt hospital issues to patient death

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

hotspot

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Private equity deals in Medicare Advantage declines

Wildfire smoke exposes gaps in outdoor worker protections

What should King Charles tell the public about his cancer?

How to save PrEP access — and even expand it

Medical mystery: When a cough is not just a cough

Dobbs anniversary: the lost opportunity of abortion as health care

PhRMA lawsuit over Medicare drug price negotiation tossed

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: How biotech is using artificial intelligence

leisure time

Senators start work on Medicare physician payment reform

John Green on his newest strategy for fighting tuberculosis

Male and female sex labels in research insufficient, scientists say

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

A disappointing year of Humira biosimilars

KalVista pill reduced swelling 'attacks' caused by genetic disease

knowledge

entertainment

leisure time

knowledge